Drugmaker Glenmark has entered into an exclusive marketing and distribution agreement with BeiGene to register and commercialize oncology drugs Tislelizumab and Zanubrutinib in India.
“The addition of tislelizumab and zanubrutinib to our oncology portfolio underscores our commitment to the cancer patient community and our commitment to providing access to novel therapies across India,” Glenmark Pharmaceuticals India Formulations president and chief business officer Alok Malik said on Tuesday.
Glenmark will be responsible for locally required development, registration and distribution, ensuring access to BeiGene’s oncology medicines for cancer patients across India, the company said, announcing the signing of the agreement by subsidiary Glenmark Specialty SA
“We are proud to advance mission-driven access, especially given the significant burden of disease in India, where rising cancer rates require comprehensive healthcare solutions,” said Adam Roach, vice president and head of Asia-Pacific at BeiGene.
Tislelizumab is a novel monoclonal antibody against programmed cell death protein 1 (PD-1) used in the treatment of advanced or metastatic esophageal squamous cell carcinoma and widely developed for the treatment of various types of cancer. Glenmark said in the release that zanubrutinib is a BTK inhibitor approved for the treatment of certain hematologic malignancies, with results from several studies supporting its favorable efficacy and safety profile.
